New drug combo tested for Tough-to-Treat breast cancer
NCT ID NCT05128734
Summary
This study is testing whether adding the drug olaparib to the chemotherapy temozolomide works better than temozolomide alone to control advanced triple-negative breast cancer. It will enroll 40 patients whose cancer has a specific genetic feature (MGMT methylation) and has worsened after prior treatments. Participants will be randomly assigned to receive one of the two drug combinations to see which is more effective at stopping or slowing cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER TRIPLE NEGATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.